Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials (Clinical Drug Investigation, (2009), 29, 5, (349-357), 10.2165/00044011-200929050-00007);Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials

Clinical Drug Investigation

Volumn 29, Issue 5, 2009, Pages 349-357

  Chen, Jian Ting ^a   Zhong, Zhao Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIUM; ERGOCALCIFEROL; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; FRACTURE; HUMAN; INCIDENCE; META ANALYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

EID: 65249100154     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-020-00999-z     Document Type: Erratum

References (48)

1. Boonen S, Kaufman JM, Goemaere S, et al. The diagnosis and treatment of male osteoporosis: defining, assessing, and preventing skeletal fragility in men. Eur J Intern Med 2007; 18: 6-17
2. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003; 67: 1521-6
3. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
4. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005; 16: 953-62
5. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217-22
6. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-8
7. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1-34
8. Clemmesen B, Ravn P, Zegels B, et al. A 2-year phase II study with 1 year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997; 7: 488-95
9. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91
10. Ste-Marie LG, Sod E, Johnson T, et al. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 469-76
11. Palomba S, Orio Jr F, Manguso F, et al. Efficacy of rise-dronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005; 16: 1141-9
12. McClung MR, Geusens P, Miller PD, et al. Effect of rise-dronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40
13. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalci-ferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007; 68: 911-5
14. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743-8
15. Ringe JD, Faber H, Farahmand P, et al. Efficacy of rise-dronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26: 427-31
16. Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69: 242-7
17. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane library. Issue 4. Chichester, UK: John Wiley & Sons, Ltd., 2006
18. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-77
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
20. Majima T, Komatsu Y, Doi K, et al. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. J Bone Miner Metab 2006; 24: 105-13
21. Majima T, Shimatsu A, Komatsu Y, et al. Efficacy of rise-dronate in Japanese male patients with primary osteoporosis. Intern Med 2008; 47: 717-23
22. Kanaji A, Higashi M, Namisato M, et al. Effects of rise-dronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Lepr Rev 2006; 77: 147-53
23. Hosking DJ, Geusens P, Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM 2005; 98: 403-13
24. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 2003; 254: 105-13
25. Olszynski WP, Shawn Davison K, Adachi JD, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004; 26: 15-28
26. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16: 87-116
27. Khan AA, Hodsman AB, Papaioannou A, et al. Management of osteoporosis in men: an update and case example. CMAJ 2007; 176: 345-8
28. Sato Y, Kaji M, Tsuru T, et al. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001; 182: 89-93
29. Ramnemark A, Nilsson M, Borssen B, et al. Stroke, a major and increasing risk factor for femoral neck fracture. Stroke 2000; 31: 1572-7
30. Ringe JD, Orwoll E, Daifotis A, et al. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 2002; 13: 195-9
31. Harris ST, Watts NB, Genant HK, et al. Effects of rise-dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Rise-dronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52
32. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000; 85: 1895-900
33. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 2003; 14: 225-34
34. Kushida K, Fukunaga M, Kishimoto H, et al. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and eti-dronate: a randomized, double-masked trial. J Bone Miner Metab 2004; 22: 469-78
35. Ogura Y, Gonsho A, Cyong JC, et al. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 2004; 22: 111-9
36. Nakamura T. Current situation of osteoporosis treatment in Japan: from the aspect of fracture prevention. Geriatr Gerontol Int 2004; 4: S69-71
37. Swaminathan R. Nutritional factors in osteoporosis. Int J Clin Pract 1999; 53: 540-8
38. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly woman. N Engl J Med 1992; 327: 1637-42
39. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081-2
40. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
41. Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004; 15: 511-9
42. Sato Y, Oizumi K, Kuno H, et al. Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Bone 1999; 24: 271-5
43. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997; 49: 1273-8
44. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18: 25-34
45. Curtis JR, Westfall AO, Cheng H, et al. Risedronat E and A Lendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 2008 Oct 23 [Epub ahead of publication]
46. Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alen-dronic acid in male osteoporosis. Clin Drug Invest 2004; 24: 333-41
47. Sawka AM, Papaioannou A, Adachi JD, et al. Does alen-dronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6: 39
48. Guyatt G, Rennie D, editors. Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press, 2001